Evidence map›Paper›PMID 37728107›Full record

ReviewHuman vaccines & immunotherapeutics2023

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.

Juan Zhao, Bin Liao, Li Gong, Huiyao Yang, Sha Li, Yongsheng Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Juan ZhaoDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Bin LiaoDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Li GongDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Huiyao YangDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Sha LiDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Yongsheng LiDepartment of Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The investigation of therapeutic cancer vaccines has been ongoing for the past century. Herein, we used VOSviewer and CiteSpace to perform the first global bibliometric analysis of the literature on therapeutic cancer vaccines from 2013 to 2022 aiming to explore the current status and potential research trends. The findings revealed a consistent upward trend in both publication counts and citations. The United States emerged as the leading contributor with the highest number of published papers. Additionally, the analysis of references and keywords indicated that therapeutic cancer vaccines have long been popular topics, whereas neoantigen vaccines, mRNA vaccines, combination strategies, and vaccine delivery systems are emerging research hotspots. This bibliometric study provides a comprehensive and important overview of the current knowledge and potential developments in therapeutic cancer vaccines from 2013 to 2022, which may serve as a valuable reference for scholars interested in further exploring this promising field.

Indexed as

Cancer VaccinesNeoplasmsBibliometricsHumansmRNA VaccinesCancer VaccinesmRNA Vaccinesbibliometric analysisCitespaceimmunotherapyknowledge mapTherapeutic cancer vaccineVOSviewer

Identifiers

PMID37728107
PMCPMC10512878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.